ReviewFrontiers in nutrition2026
Cardioprotective effects of naringin, hesperidin, and hesperetin: modulation of atherosclerosis, cardiac remodeling, and myocardial ischemia/infarction.
Review in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases (CVDs) persist as the predominant contributor to morbidity and mortality on a global scale, principally attributed to the pathophysiological processes of atherosclerosis, cardiac remodeling, and myocardial ischemia/infarction. Contemporary research underscores the cardioprotective efficacy of natural flavonoids, including naringin, hesperidin (HES), and hesperetin (HST), bioactive constituents prevalent in citrus fruits. These flavonoids demonstrate multifaceted effects, encompassing antioxidant, anti-inflammatory, anti-apoptotic, lipid-lowering, and endothelial-protective properties, all of which synergistically enhance cardiovascular performance. At the molecular nexus, naringin, HES, and HST influence critical signaling pathways, thus diminishing oxidative stress, obstructing the action of inflammatory cytokines, and curtailing the proliferation of vascular smooth muscle cells. Furthermore, these bioactive compounds regulate cardiac remodeling by alleviating fibrosis, hypertrophy, and mitochondrial dysfunction, whilst simultaneously promoting angiogenesis and optimizing energy metabolism. In experimental models of myocardial ischemia and infarction, they facilitate cardiomyocyte viability and diminish infarct size through the modulation of apoptosis-related genes and the mitigation of oxidative injury. This review meticulously synthesizes the mechanistic insights and preclinical data that substantiate the cardioprotective properties of naringin, HES, and HST. Additionally, it examines their pharmacokinetic profiles, bioavailability, and prospective clinical applications as adjunctive agents in the prophylaxis and management of CVDs. Elucidating these molecular pathways could offer a promising framework for the formulation of predictive, preventive, and personalized strategies aimed at combatting CVDs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.